Increased Phospho-AKT in Blood Cells from LRRK2 G2019S Mutation Carriers

Overview

Journal Ann Neurol

Specialty Neurology

Date 2022 Aug 5

PMID 35929078

Authors

Alicia Garrido

Leticia Perez-Sisques

Cristina Simonet

Genis Campoy-Campos

Julia Solana-Balaguer

Nuria Martin-Flores

Manel Fernandez

Marta Soto

Donina Obiang

Ana Camara

Francesc Valldeoriola

Esteban Munoz

Yaroslau Compta

Esther Perez-Navarro

Jordi Alberch

Eduardo Tolosa

Maria-Jose Marti

Mario Ezquerra

Cristina Malagelada

Ruben Fernandez-Santiago

Affiliations

Soon will be listed here.

Abstract

The purpose of this study was to investigate whether differential phosphorylation states of blood markers can identify patients with LRRK2 Parkinson's disease (PD). We assessed phospho(P)-Ser-935-LRRK2 and P-Ser-473-AKT levels in peripheral blood cells from patients with G2019S LRRK2-associated PD (L2PD, n = 31), G2019S LRRK2 non-manifesting carriers (L2NMC, n = 26), idiopathic PD (iPD, n = 25), and controls (n = 40, total n = 122). We found no differences at P-Ser-935-LRRK2 between groups but detected a specific increase of P-Ser-473-AKT levels in all G2019S carriers, either L2PD or L2NMC, absent in iPD. Although insensitive to LRRK2 inhibition, our study identifies P-Ser-473-AKT as an endogenous candidate biomarker for peripheral inflammation in G2019S carriers using accessible blood cells. ANN NEUROL 2022;92:888-894.

References

Lu J, Wang C, Cheng X, Wang R, Yan X, He P . A breakdown in microglial metabolic reprogramming causes internalization dysfunction of α-synuclein in a mouse model of Parkinson's disease. J Neuroinflammation. 2022; 19(1):113. PMC: 9124408. DOI: 10.1186/s12974-022-02484-0. View

Bommhardt U, Chang K, Swanson P, Wagner T, Tinsley K, Karl I . Akt decreases lymphocyte apoptosis and improves survival in sepsis. J Immunol. 2004; 172(12):7583-91. DOI: 10.4049/jimmunol.172.12.7583. View

Malagelada C, Jin Z, Greene L . RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation/activation. J Neurosci. 2009; 28(53):14363-71. PMC: 3865436. DOI: 10.1523/JNEUROSCI.3928-08.2008. View

Zhang M, Yao C, Cai J, Liu S, Liu X, Chen Y . LRRK2 is involved in the pathogenesis of system lupus erythematosus through promoting pathogenic antibody production. J Transl Med. 2019; 17(1):37. PMC: 6343316. DOI: 10.1186/s12967-019-1786-6. View

Tolosa E, Vila M, Klein C, Rascol O . LRRK2 in Parkinson disease: challenges of clinical trials. Nat Rev Neurol. 2020; 16(2):97-107. DOI: 10.1038/s41582-019-0301-2. View

Hughes A, Daniel S, Kilford L, Lees A . Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992; 55(3):181-4. PMC: 1014720. DOI: 10.1136/jnnp.55.3.181. View

Alliot F, Godin I, Pessac B . Microglia derive from progenitors, originating from the yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 1999; 117(2):145-52. DOI: 10.1016/s0165-3806(99)00113-3. View

Seol W, Nam D, Son I . Rab GTPases as Physiological Substrates of LRRK2 Kinase. Exp Neurobiol. 2019; 28(2):134-145. PMC: 6526114. DOI: 10.5607/en.2019.28.2.134. View

Manning B, Toker A . AKT/PKB Signaling: Navigating the Network. Cell. 2017; 169(3):381-405. PMC: 5546324. DOI: 10.1016/j.cell.2017.04.001. View

10.

West A, Moore D, Biskup S, Bugayenko A, Smith W, Ross C . Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A. 2005; 102(46):16842-7. PMC: 1283829. DOI: 10.1073/pnas.0507360102. View

11.

Guttuso Jr T, Andrzejewski K, Lichter D, Andersen J . Targeting kinases in Parkinson's disease: A mechanism shared by LRRK2, neurotrophins, exenatide, urate, nilotinib and lithium. J Neurol Sci. 2019; 402:121-130. DOI: 10.1016/j.jns.2019.05.016. View

12.

Sousa L, Lopes F, Silva D, Tavares L, Vieira A, Rezende B . PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-kappaB-independent manner. J Leukoc Biol. 2010; 87(5):895-904. DOI: 10.1189/jlb.0809540. View

13.

Simon-Sanchez J, Marti-Masso J, Sanchez-Mut J, Paisan-Ruiz C, Martinez-Gil A, Ruiz-Martinez J . Parkinson's disease due to the R1441G mutation in Dardarin: a founder effect in the Basques. Mov Disord. 2006; 21(11):1954-9. DOI: 10.1002/mds.21114. View

14.

Wallings R, Tansey M . LRRK2 regulation of immune-pathways and inflammatory disease. Biochem Soc Trans. 2019; 47(6):1581-1595. PMC: 6925522. DOI: 10.1042/BST20180463. View

15.

Creus-Muncunill J, Rue L, Alcala-Vida R, Badillos-Rodriguez R, Romani-Aumedes J, Marco S . Increased Levels of Rictor Prevent Mutant Huntingtin-Induced Neuronal Degeneration. Mol Neurobiol. 2018; 55(10):7728-7742. DOI: 10.1007/s12035-018-0956-5. View

16.

Garrido A, Santamaria E, Fernandez-Irigoyen J, Soto M, Simonet C, Fernandez M . Differential Phospho-Signatures in Blood Cells Identify LRRK2 G2019S Carriers in Parkinson's Disease. Mov Disord. 2022; 37(5):1004-1015. PMC: 9306798. DOI: 10.1002/mds.28927. View

17.

Hamza T, Zabetian C, Tenesa A, Laederach A, Montimurro J, Yearout D . Common genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease. Nat Genet. 2010; 42(9):781-5. PMC: 2930111. DOI: 10.1038/ng.642. View

18.

Funk N, Munz M, Ott T, Brockmann K, Wenninger-Weinzierl A, Kuhn R . The Parkinson's disease-linked Leucine-rich repeat kinase 2 (LRRK2) is required for insulin-stimulated translocation of GLUT4. Sci Rep. 2019; 9(1):4515. PMC: 6418296. DOI: 10.1038/s41598-019-40808-y. View

19.

Saavedra A, Garcia-Martinez J, Xifro X, Giralt A, Torres-Peraza J, Canals J . PH domain leucine-rich repeat protein phosphatase 1 contributes to maintain the activation of the PI3K/Akt pro-survival pathway in Huntington's disease striatum. Cell Death Differ. 2009; 17(2):324-35. DOI: 10.1038/cdd.2009.127. View

20.

Fan Y, Howden A, Sarhan A, Lis P, Ito G, Martinez T . Interrogating Parkinson's disease LRRK2 kinase pathway activity by assessing Rab10 phosphorylation in human neutrophils. Biochem J. 2017; 475(1):23-44. PMC: 5748842. DOI: 10.1042/BCJ20170803. View